The FDA has approved a new treatment for patients with a common form of breast cancer that has spread to other parts of the body or cannot be surgically removed.
Biopharma executives shared their thoughts on the potential impacts of the new administration; Annalee Armstrong recaps JPM ...
The FDA has approved Datroway (datopotamab deruxtecan) to treat adults with unresectable or metastatic, HR+, HER2- breast cancer who have received prior endocrine therapy and chemotherapy.
Analyst Andrew Berens of Leerink Partners maintained a Buy rating on AstraZeneca (AZN – Research Report), retaining the price target of ...
On Friday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ:AZN) Datroway (datopotamab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback